At a glance
ClinicalIndex Comparison Record- ✓Squamous cell carcinoma or adenocarcinoma of the esophagus
- ✓Stage II-IVA disease by clinical staging (endoscopy, CT ± EUS)
- ✓For GEJ tumors, bulk must be in the esophagus
- ✓ECOG performance status 0-1
- ✕Known brain metastases
- ✕Prior therapy for esophageal cancer
- ✕Peripheral neuropathy grade ≥2
- ✕Hypersensitivity to platinum compounds, fluoropyrimidines, or antiemetics
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Capecitabine in Combination With Oxaliplatin and Radiotherapy for Esophageal and Gastroesophageal Junction Cancer
In Brief
A Phase 2 clinical trial evaluating capecitabine, oxaliplatin, and 9 other interventions for Esophageal Cancer. Completed, enrolled 41 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well giving oxaliplatin and capecitabine together with radiation therapy works in treating patients undergoing surgery for stage II, stage III, or stage IV esophageal cancer.
Study Details
Timeline
Interventions
Oral
IV
Correlative Study
Correlative Study
Correlative Study
Metastatic growth control
Examination of tissue type
Tissue removal
Tumor shrinkage
Correlative Study
Undergoing radiation therapy